POSA162 Modeling the Ex Ante Real Option Value in a Highly Innovative Therapeutic Area: ALK-Positive Non-Small Cell Lung Cancer
Abstract
Authors
W Lee W Wong S Kowal L Garrison DL Veenstra M Li
W Lee W Wong S Kowal L Garrison DL Veenstra M Li
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now